Home Newsfeeds Goldman Sachs Upgrades Align Tech to Neutral, Announces $307 Price Target

Goldman Sachs Upgrades Align Tech to Neutral, Announces $307 Price Target

Goldman Sachs analyst Nathan Rice upgrades Align Tech (NASDAQ:ALGN) from Sell to Neutral and announces $307 price target.

byBenzinga Newsdesk

February 2, 2023

1 minute read

Goldman Sachs analyst Nathan Rice upgrades Align Tech (NASDAQ:ALGN) from Sell to Neutral and announces $307 price target.

Duluth Holdings Q1: Earnings Beat, Reaffirmed FY23 Outlook & More

By Shivani Kumaresan

June 1, 9:29 AM

Duluth Holdings Inc (NASDAQ:DLTH) reported first-quarter FY23 sales growth of 0.7% year-on-year to $123.76 million, beating the consensus of $118.66 million.…

DLTH

Over $37M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying

By Avi Kapoor

February 20, 7:53 AM

Although U.S. stocks closed lower on Friday, there were a few notable insider trades.

ADC

Tilray To Guide Patients On Their Medical Cannabis Journey, Launches New Products & ‘CannaPoints’ Program

By Vuk Zdinjak

August 25, 7:53 AM

Tilray Brands, Inc.’s (Nasdaq: TLRY) (TSX:TLRY) Tilray Medical, has released new medical cannabis products, under Tilray and Aphria brands and launched CannaPoints, a new program designed to support pa

TLRY

These Analysts Raise Their Forecasts On Palantir Technologies After Q4 Results

By Avi Kapoor

February 6, 8:31 AM

Palantir Technologies Inc (NYSE: PLTR) reported upbeat sales results for its fourth quarter on Monday.

PLTR

Goldman Sachs Upgrades Align Tech to Neutral, Announces $307 Price Target

Related Posts

Duluth Holdings Q1: Earnings Beat, Reaffirmed FY23 Outlook & More

Over $37M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying

Tilray To Guide Patients On Their Medical Cannabis Journey, Launches New Products & ‘CannaPoints’ Program

These Analysts Raise Their Forecasts On Palantir Technologies After Q4 Results